Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free ARVN Stock Alerts

Arvinas (ARVN) Competitors

Arvinas logo
$7.41 -0.02 (-0.27%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$7.42 +0.00 (+0.07%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ARVN vs. SRPT, BHVN, KOD, NUVB, and ZBIO

Should you buy Arvinas stock or one of its competitors? Arvinas's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Biohaven (BHVN), Kodiak Sciences (KOD), Nuvation Bio (NUVB), and Zenas BioPharma (ZBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arvinas compare to Sarepta Therapeutics?

Arvinas (NASDAQ:ARVN) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Arvinas. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 9 mentions for Arvinas. Sarepta Therapeutics' average media sentiment score of 0.57 beat Arvinas' score of 0.22 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sarepta Therapeutics
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Arvinas currently has a consensus target price of $14.55, suggesting a potential upside of 96.29%. Sarepta Therapeutics has a consensus target price of $23.81, suggesting a potential upside of 36.07%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30
Sarepta Therapeutics
6 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.10

Arvinas has a net margin of 2.94% compared to Sarepta Therapeutics' net margin of -13.48%. Arvinas' return on equity of 1.91% beat Sarepta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas2.94% 1.91% 1.29%
Sarepta Therapeutics -13.48%-1.60%-0.66%

Arvinas has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.82-$80.80M$0.1074.10
Sarepta Therapeutics$2.20B0.84-$713.41M-$2.90N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arvinas has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Summary

Arvinas beats Sarepta Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Arvinas compare to Biohaven?

Arvinas (NASDAQ:ARVN) and Biohaven (NYSE:BHVN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Arvinas has a net margin of 2.94% compared to Biohaven's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas2.94% 1.91% 1.29%
Biohaven N/A -1,328.94%-138.27%

Arvinas has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Arvinas currently has a consensus target price of $14.55, suggesting a potential upside of 96.29%. Biohaven has a consensus target price of $18.69, suggesting a potential upside of 45.10%. Given Arvinas' higher possible upside, equities analysts plainly believe Arvinas is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30
Biohaven
2 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.59

Arvinas has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.82-$80.80M$0.1074.10
BiohavenN/AN/A-$738.82M-$4.64N/A

In the previous week, Arvinas had 8 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for Arvinas and 1 mentions for Biohaven. Arvinas' average media sentiment score of 0.22 beat Biohaven's score of -0.40 indicating that Arvinas is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biohaven
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.2% of Arvinas shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Arvinas beats Biohaven on 12 of the 16 factors compared between the two stocks.

How does Arvinas compare to Kodiak Sciences?

Arvinas (NASDAQ:ARVN) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Kodiak Sciences had 54 more articles in the media than Arvinas. MarketBeat recorded 63 mentions for Kodiak Sciences and 9 mentions for Arvinas. Kodiak Sciences' average media sentiment score of 0.59 beat Arvinas' score of 0.22 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kodiak Sciences
17 Very Positive mention(s)
8 Positive mention(s)
25 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Arvinas has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.82-$80.80M$0.1074.10
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

95.2% of Arvinas shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arvinas has a net margin of 2.94% compared to Kodiak Sciences' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas2.94% 1.91% 1.29%
Kodiak Sciences N/A -273.23%-85.48%

Arvinas has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

Arvinas presently has a consensus price target of $14.55, indicating a potential upside of 96.29%. Kodiak Sciences has a consensus price target of $100.43, indicating a potential upside of 6.33%. Given Arvinas' higher possible upside, equities research analysts clearly believe Arvinas is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

Arvinas beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

How does Arvinas compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Arvinas has a net margin of 2.94% compared to Nuvation Bio's net margin of -88.18%. Arvinas' return on equity of 1.91% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-88.18% -46.59% -22.01%
Arvinas 2.94%1.91%1.29%

Nuvation Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

In the previous week, Arvinas had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for Arvinas and 8 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.33 beat Arvinas' score of 0.22 indicating that Nuvation Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arvinas
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arvinas has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$62.90M28.59-$204.63M-$0.44N/A
Arvinas$262.60M1.82-$80.80M$0.1074.10

Nuvation Bio currently has a consensus price target of $13.22, indicating a potential upside of 158.20%. Arvinas has a consensus price target of $14.55, indicating a potential upside of 96.29%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Arvinas
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Arvinas beats Nuvation Bio on 10 of the 16 factors compared between the two stocks.

How does Arvinas compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Arvinas has a net margin of 2.94% compared to Zenas BioPharma's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A -122.45% -58.04%
Arvinas 2.94%1.91%1.29%

95.2% of Arvinas shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Zenas BioPharma presently has a consensus target price of $46.71, suggesting a potential upside of 65.07%. Arvinas has a consensus target price of $14.55, suggesting a potential upside of 96.29%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Arvinas
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30

In the previous week, Zenas BioPharma had 3 more articles in the media than Arvinas. MarketBeat recorded 12 mentions for Zenas BioPharma and 9 mentions for Arvinas. Zenas BioPharma's average media sentiment score of 0.40 beat Arvinas' score of 0.22 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zenas BioPharma
1 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arvinas
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arvinas has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$1M1,844.51-$377.74M-$8.99N/A
Arvinas$262.60M1.82-$80.80M$0.1074.10

Zenas BioPharma has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Summary

Arvinas beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

Export
MetricArvinasBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$479.39M$3.87B$7.14B$13.17B
Dividend YieldN/A3.64%2.53%16.78%
P/E Ratio74.1113.06275.6826.04
Price / Sales1.511,373.91658.18100.99
Price / CashN/A122.6077.6051.75
Price / Book1.1016.6310.936.31
Net Income-$80.80M-$22.71M$3.51B$362.16M
7 Day Performance-2.37%-2.99%-2.01%-1.66%
1 Month Performance-20.41%-10.60%-6.15%-4.50%
1 Year Performance-22.89%19.44%7.44%2.06%

Arvinas Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARVN
Arvinas
2.8901 of 5 stars		$7.41
-0.3%		$14.55
+96.3%		-20.1%$479.39M$316.70M74.11246
SRPT
Sarepta Therapeutics
3.2547 of 5 stars		$20.14
+0.1%		$24.07
+19.5%		-21.7%$2.12B$1.97BN/A835
BHVN
Biohaven
2.4637 of 5 stars		$14.21
+4.3%		$18.69
+31.5%		-16.8%$2.06BN/AN/A274
KOD
Kodiak Sciences
2.5481 of 5 stars		$32.42
-0.9%		$48.14
+48.5%		+603.3%$2.06BN/AN/A124
NUVB
Nuvation Bio
2.7402 of 5 stars		$6.08
+3.9%		$13.00
+113.8%		+38.2%$2.05B$62.90MN/A305

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 10/3/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel